Hollencrest Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Hollencrest Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63.3K	Sell	400 -800	-67%	-$108K	﹤0.01%	531
2026 Q1	$153K	Buy	+1,200	New	+$150K	0.01%	344

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Hollencrest Capital Management's XBI Position: Q2 2026 in Review

Hollencrest Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 34% in Q2 2026, buying an estimated $18.9K and bringing the position to 550 shares worth $87K. The position accounts for 0.01% of the portfolio, ranked #473.

Hollencrest Capital Management first reported a position in XBI in Q2 2018 and has held it in 17 quarters since. The position peaked at $247K in Q2 2018. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Hollencrest Capital Management held 550 shares of State Street SPDR S&P Biotech ETF worth $87K as of Q2 2026.
Hollencrest Capital Management bought 140 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $18.9K.
State Street SPDR S&P Biotech ETF made up 0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #473 holding.
Hollencrest Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and has held it in 17 quarters since.
Hollencrest Capital Management's State Street SPDR S&P Biotech ETF position peaked at $247K in Q2 2018.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.